GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » 3-Year RORE %

Island Pharmaceuticals (ASX:ILA) 3-Year RORE % : -8.42% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Island Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2024 was -8.42%.

The industry rank for Island Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

ASX:ILA's 3-Year RORE % is ranked better than
52.1% of 1378 companies
in the Biotechnology industry
Industry Median: -10.2 vs ASX:ILA: -8.42

Island Pharmaceuticals 3-Year RORE % Historical Data

The historical data trend for Island Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals 3-Year RORE % Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24
3-Year RORE %
- - - 2.13

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only - - 22.67 2.13 -8.42

Competitive Comparison of Island Pharmaceuticals's 3-Year RORE %

For the Biotechnology subindustry, Island Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's 3-Year RORE % falls into.


;
;

Island Pharmaceuticals 3-Year RORE % Calculation

Island Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.03--0.038 )/( -0.095-0 )
=0.008/-0.095
=-8.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 3-year before.


Island Pharmaceuticals  (ASX:ILA) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Island Pharmaceuticals 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Island Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines